142 related articles for article (PubMed ID: 9132317)
1. A case of diffuse systemic sclerosis treated with a 28-day infusion of iloprost.
Biasi D; Caramaschi P; Carletto A; Zeminian S; Schiavon F; Bambara LM
Clin Rheumatol; 1997 Jan; 16(1):111-2. PubMed ID: 9132317
[No Abstract] [Full Text] [Related]
2. Effects of five-day versus one-day infusion of iloprost on the peripheral microcirculation in patients with systemic sclerosis.
Ceru S; Pancera P; Sansone S; Sfondrini G; Codella O; De Sandre G; Lechi A; Lunardi C
Clin Exp Rheumatol; 1997; 15(4):381-5. PubMed ID: 9272298
[TBL] [Abstract][Full Text] [Related]
3. [Iloprost administration over 21 days as an effective therapy in systemic scleroderma--case report and review of the literature].
Riemekasten G; Jepsen H; Burmester GR; Hiepe F
Z Rheumatol; 1998 Apr; 57(2):118-24. PubMed ID: 9627952
[TBL] [Abstract][Full Text] [Related]
4. Does cyclically iloprost infusion prevent severe isolated pulmonary hypertension in systemic sclerosis? Preliminary results.
Caramaschi P; Volpe A; Tinazzi I; Bambara LM; Carletto A; Biasi D
Rheumatol Int; 2006 Dec; 27(2):203-5. PubMed ID: 17006704
[TBL] [Abstract][Full Text] [Related]
5. Iloprost infusion does not reduce oxidative stress in systemic sclerosis.
Volpe A; Biasi D; Caramaschi P; Bambara LM; Carletto A; Degan M; Minuz P
Rheumatol Int; 2008 Feb; 28(4):335-7. PubMed ID: 17704920
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of finger skin temperature in scleroderma patients cyclically treated with iloprost.
Caramaschi P; Biasi D; Canestrini S; Martinelli N; Perbellini L; Carletto A; Pieropan S; Volpe A; Bambara LM
Joint Bone Spine; 2006 Jan; 73(1):57-61. PubMed ID: 16253538
[TBL] [Abstract][Full Text] [Related]
7. Discontinuing long-term Iloprost treatment for Raynaud's Phenomenon and systemic sclerosis: a single-center, randomized, placebo-controlled, double-blind study.
Bali G; Schwantzer G; Aberer F; Kraenke B; Aberer E
Acta Dermatovenerol Alp Pannonica Adriat; 2011; 20(1):13-21. PubMed ID: 21879200
[TBL] [Abstract][Full Text] [Related]
8. Diffuse cutaneous systemic sclerosis treated with intravenous iloprost.
Foti C; Cassano N; Conserva A; Coviello C; De Meo M; Vena GA
Clin Exp Dermatol; 2004 May; 29(3):321-3. PubMed ID: 15115528
[No Abstract] [Full Text] [Related]
9. [Iloprost therapy in systemic sclerosis].
Bali G; Aberer E
Hautarzt; 2003 Sep; 54(9):845-51. PubMed ID: 12955262
[TBL] [Abstract][Full Text] [Related]
10. Long-term clinical stabilization of scleroderma patients treated with a chronic and intensive IV iloprost regimen.
Foti R; Visalli E; Amato G; Benenati A; Converso G; Farina A; Bellofiore S; Mulè M; Di Gangi M
Rheumatol Int; 2017 Feb; 37(2):245-249. PubMed ID: 27796521
[TBL] [Abstract][Full Text] [Related]
11. Prostacyclin analogue iloprost influences endothelial cell-associated soluble adhesion molecules and growth factors in patients with systemic sclerosis: a time course study of serum concentrations.
Rehberger P; Beckheinrich-Mrowka P; Haustein UF; Sticherling M
Acta Derm Venereol; 2009; 89(3):245-9. PubMed ID: 19479119
[TBL] [Abstract][Full Text] [Related]
12. Intermittent iloprost infusion therapy of pulmonary hypertension in scleroderma--a pilot study.
Bartosik I; Eskilsson J; Scheja A; Akesson A
Br J Rheumatol; 1996 Nov; 35(11):1187-8. PubMed ID: 8948314
[No Abstract] [Full Text] [Related]
13. Exhaled nitric oxide and pulmonary response to iloprost in systemic sclerosis.
Marczin N; Riedel B; Royston D; Yacoub M
Lancet; 1998 Aug; 352(9125):405-6. PubMed ID: 9717956
[No Abstract] [Full Text] [Related]
14. [Treatment of therapy-resistant acral ulcers with iloprost].
von Schmiedeberg S; Artik S; Assmann T; Megahed M; Ruzicka T
Hautarzt; 2004 Dec; 55(12):1150-3. PubMed ID: 15568132
[TBL] [Abstract][Full Text] [Related]
15. Effect of a sequential therapy of bosentan and iloprost versus a monotherapy with bosentan in the treatment of scleroderma related digital ulcers.
Hafner F; Thomas G; Froehlich H; Steidl K; Brodmann M
Int Angiol; 2011 Oct; 30(5):493-5. PubMed ID: 21804491
[No Abstract] [Full Text] [Related]
16. Gene expression profiling in circulating endothelial cells from systemic sclerosis patients shows an altered control of apoptosis and angiogenesis that is modified by iloprost infusion.
Tinazzi E; Dolcino M; Puccetti A; Rigo A; Beri R; Valenti MT; Corrocher R; Lunardi C
Arthritis Res Ther; 2010; 12(4):R131. PubMed ID: 20609215
[TBL] [Abstract][Full Text] [Related]
17. Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study.
Kawald A; Burmester GR; Huscher D; Sunderkötter C; Riemekasten G
J Rheumatol; 2008 Sep; 35(9):1830-7. PubMed ID: 18634152
[TBL] [Abstract][Full Text] [Related]
18. Iloprost therapy acutely decreases oxidative stress in patients affected by systemic sclerosis.
Erre GL; De Muro P; Dellacà P; Fenu P; Cherchi GM; Faedda R; Passiu G
Clin Exp Rheumatol; 2008; 26(6):1095-8. PubMed ID: 19210877
[TBL] [Abstract][Full Text] [Related]
19. Acute and chronic effects of two different intravenous iloprost regimens in systemic sclerosis: a pragmatic non-randomized trial.
Schioppo T; Orenti A; Boracchi P; De Lucia O; Murgo A; Ingegnoli F
Rheumatology (Oxford); 2018 Aug; 57(8):1408-1416. PubMed ID: 29733400
[TBL] [Abstract][Full Text] [Related]
20. Iloprost treatment summer-suspension: effects on skin thermal properties and cytokine profile in systemic sclerosis patients.
Auriemma M; Vianale G; Reale M; Costantini E; Di Nicola M; Romani GL; Merla A; Muraro R; Amerio P
G Ital Dermatol Venereol; 2013 Apr; 148(2):209-16. PubMed ID: 23588147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
